Losartan for the treatment of hypertension and left ventricular hypertrophy: the Losartan intervention for endpoint reduction in hypertension (LIFE) study

被引：7
|
作者：
Devereux, RB
Lyle, PA
机构：
[1] Cornell Univ, Weill Med Coll, Div Cardiol, New York, NY 10021 USA
[2] Merck Res Labs, West Point, PA 19486 USA
来源：
EXPERT OPINION ON PHARMACOTHERAPY | 2004年 / 5卷 / 11期
关键词：
albuminuria; angiotensin II; angiotensin-receptor antagonist; antihypertensive agents; diabetes mellitus; hypertension; isolated systolic hypertension; left ventricular hypertrophy; Losartan; stroke; uric acid;
D O I：
10.1517/14656566.5.11.2311
中图分类号：
R9 [药学];
学科分类号：
1007 ;
摘要：
Losartan is an orally active, selective, nonpeptide, angiotensin-II Type I-receptor antagonist, and was the first drug marketed in this class. It has been approved for the treatment of hypertension, and may be used alone or in combination with other anti hypertensive agents. Based on the Losartan Intervention For Endpoint reduction in hypertension (LIFE) study, losartan has been approved for the reduction of cardiovascular events in patients with hypertension and left ventricular hypertrophy, but there is evidence that this benefit does not apply to black patients. Based on the Reduction of Endpoints in NOW with the Angiotensin II Antagonist Losartan (RENAAL) study, losartan is also indicated for the treatment of diabetic nephropathy with an elevated serum creatinine and proteinuria, in patients with Type 2 diabetes. The focus of this review is the LIFE study.
引用
收藏
页码：2311 / 2320
页数：10
相关论文
共 50 条
  • [21] Association of Pulse Pressure With New-Onset Atrial Fibrillation in Patients With Hypertension and Left Ventricular Hypertrophy The Losartan Intervention For Endpoint (LIFE) Reduction in Hypertension Study
    Larstorp, Anne Cecilie K.
    Ariansen, Inger
    Gjesdal, Knut
    Olsen, Michael H.
    Ibsen, Hans
    Devereux, Richard B.
    Okin, Peter M.
    Dahlof, Bjorn
    Kjeldsen, Sverre E.
    Wachtell, Kristian
    HYPERTENSION, 2012, 60 (02) : 347 - +
  • [22] Potential mechanisms of stroke benefit favoring losartan in the Losartan Intervention For Endpoint reduction in hypertension (LIFE) study
    Devereux, Richard B.
    Dahlof, Bjorn
    CURRENT MEDICAL RESEARCH AND OPINION, 2007, 23 (02) : 443 - 457
  • [23] Progressive hypertrophy regression with sustained pressure reduction in hypertension:: the Losartan Intervention For Endpoint Reduction study
    Devereux, RB
    Palmieri, V
    Liu, JE
    Wachtell, K
    Bella, JN
    Boman, K
    Gerdts, E
    Nieminen, MS
    Papademetriou, V
    Dahlöf, B
    JOURNAL OF HYPERTENSION, 2002, 20 (07) : 1445 - 1450
  • [24] The Losartan Intervention for Endpoint reduction (LIFE) in Hypertension study - Rationale, design, and methods
    Dahlof, B
    Devereux, R
    deFaire, U
    Fyhrquist, F
    Hedner, T
    Ibsen, H
    Julius, S
    Kjeldsen, S
    Kristianson, K
    LederballePedersen, O
    Lindholm, LH
    Nieminen, MS
    Omvik, P
    Oparil, S
    Wedel, H
    AMERICAN JOURNAL OF HYPERTENSION, 1997, 10 (07) : 705 - 713
  • [25] Change of left ventricular geometric, pattern after 1 year of antihypertensive treatment:: The Losartan Intervention For Endpoint reduction in hypertension (LIFE) study
    Wachtell, K
    Dahlöf, B
    Rokkedal, J
    Papademetriou, V
    Nieminen, MS
    Smith, G
    Gerdts, E
    Boman, K
    Bella, JN
    Devereux, RB
    AMERICAN HEART JOURNAL, 2002, 144 (06) : 1057 - 1064
  • [26] Change in diastolic left ventricular filling after one year of antihypertensive treatment -: The losartan intervention for endpoint reduction in hypertension (LIFE) study
    Wachtell, K
    Bella, JN
    Rokkedal, J
    Palmieri, V
    Papademetriou, V
    Dahlöf, B
    Aalto, T
    Gerdts, E
    Devereux, RB
    CIRCULATION, 2002, 105 (09) : 1071 - 1076
  • [27] Stroke reduction in hypertensive adults with cardiac hypertrophy randomized to losartan versus atenolol -: The Losartan Intervention for Endpoint reduction in hypertension study
    Kizer, JR
    Dahlöf, B
    Kjeldsen, SE
    Julius, S
    Beevers, G
    de Faire, U
    Fyhrquist, F
    Ibsen, H
    Kristianson, K
    Lederballe-Pedersen, O
    Lindholm, LH
    Nieminen, MS
    Omvik, P
    Oparil, S
    Wedel, H
    Wachtell, K
    Edelman, JM
    Snapinn, SM
    Harris, KE
    Devereux, RB
    HYPERTENSION, 2005, 45 (01) : 46 - 52
  • [28] Gender differences in left ventricular structure and function during antihypertensive treatment - The Losartan intervention for Endpoint reduction in hypertension study
    Gerdts, Eva
    Okin, Peter M.
    De Simone, Giovanni
    Cramariuc, Dana
    Wachtell, Kristian
    Boman, Kurt
    Devereux, Richard B.
    HYPERTENSION, 2008, 51 (04) : 1109 - 1114
  • [29] Left bundle branch block and cardiovascular morbidity and mortality in hypertensive patients with left ventricular hypertrophy:: the Losartan Intervention For Endpoint Reduction in Hypertension study
    Li, Zhibin
    Dahlof, Bjorn
    Okin, Peter M.
    Kjeldsen, Sverre E.
    Wachtell, Kristian
    Ibsen, Hans
    Nieminen, Markku S.
    Jern, Sverker
    Devereux, Richard B.
    JOURNAL OF HYPERTENSION, 2008, 26 (06) : 1244 - 1249
  • [30] Serum uric acid and ischemic stroke risk among hypertensive patients with left ventricular hypertrophy: The losartan intervention for endpoint reduction in hypertension (LIFE) study
    Kizer, JR
    Hoieggen, A
    Alderman, MH
    Kjeldsen, SE
    Dahlof, B
    Julius, S
    Beevers, G
    de Faire, U
    Fyhrquist, F
    Ibsen, H
    Kristiansson, K
    Lederballe-Pedersen, O
    Lindholm, LH
    Nieminen, MS
    Oparil, S
    Wedel, H
    Edelman, JM
    Snapinn, SM
    Devereux, RB
    JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 2004, 43 (05) : 475A - 475A
12345